Litigation Details for Pozen Inc. v. Par Pharmaceutical, Inc. (E.D. Tex. 2008)

Pozen Inc. v. Par Pharmaceutical, Inc. (E.D. Tex. 2008)

Docket		Date Filed	2008-11-14
Court	District Court, E.D. Texas	Date Terminated	2011-08-05
Cause	35:271 Patent Infringement	Assigned To	Leonard E. Davis
Jury Demand	None	Referred To
Parties	DR. REDDY'S LABORATORIES, INC.
Patents	7,332,183
Attorneys	Stephen M. Hash
Firms	JAMS Inc
Link to Docket	External link to docket

Details for Pozen Inc. v. Par Pharmaceutical, Inc. (E.D. Tex. 2008)

Date Filed	Document No.	Description	Snippet	Link To Document
2008-11-14				External link to document

Pozen Inc. v. Par Pharmaceutical, Inc. Litigation Summary, 6:08-cv-00437

Last updated: August 4, 2026

Pozen Inc. v. Par Pharmaceutical, Inc., No. 6:08-cv-00437, was a patent infringement action involving Par's abbreviated new drug application for a generic version of Treximet, Pozen's combination product containing sumatriptan and naproxen sodium. The Eastern District of Texas found infringement and upheld the asserted Pozen patents against invalidity challenges. The Federal Circuit affirmed the principal judgment in 2012. The case established a strong patent position for the specific combination, dosage relationship, and administration method used in Treximet. [1], [2]

What drug and patents were at issue in Pozen v. Par?

The litigation concerned Treximet, a fixed-dose oral tablet combining:

Product element	Treximet characteristic
Triptan	Sumatriptan succinate
NSAID	Naproxen sodium
Approved indication	Acute treatment of migraine attacks, with or without aura
NDA holder at approval	GlaxoSmithKline
Product technology originator	Pozen Inc.
Generic pathway	ANDA under the Hatch-Waxman Act

Pozen's patents claimed the combination of sumatriptan and naproxen, particular dosage ranges, and methods for treating migraine by administering the two active ingredients together or in a coordinated manner.

The principal asserted patents were:

Patent	General subject matter	Litigation relevance
U.S. Patent No. 6,060,499	Combination pharmaceutical compositions containing sumatriptan and naproxen	Asserted against Par's ANDA product
U.S. Patent No. 6,586,458	Methods for treating migraine with the combination	Asserted against Par's proposed generic use

The patents descended from Pozen's research into combining a triptan with an NSAID to address both migraine pain and associated inflammation. The claimed invention was not merely the coadministration of two known drugs. Pozen relied on the claimed dosage relationship, formulation structure, and therapeutic method.

When was Pozen v. Par filed and decided?

The case was filed in 2008 in the U.S. District Court for the Eastern District of Texas under civil action number 6:08-cv-00437. The litigation followed Par's filing of an ANDA containing a Paragraph IV certification challenging Pozen's listed patents.

The principal procedural timeline was:

Date	Event
2008	Par filed an ANDA for a generic sumatriptan/naproxen product and provided a Paragraph IV notice
2008	Pozen filed the infringement action under 35 U.S.C. § 271(e)(2)
2011	The district court issued its principal decision after claim construction and trial proceedings
2012	The Federal Circuit affirmed the district court's principal rulings
2012	Federal Circuit decision reported at 696 F.3d 1151

The Federal Circuit decision is reported as Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151 (Fed. Cir. 2012). [2]

What did the district court decide?

The district court held that Par's proposed product infringed asserted claims of the '499 and '458 patents. It also rejected Par's principal invalidity defenses.

The case involved several recurring Hatch-Waxman issues:

1. The meaning of claim terms directed to the composition and dosage relationship.
2. Whether Par's proposed generic product met the limitations of the asserted claims.
3. Whether the asserted claims were obvious in view of prior migraine treatments.
4. Whether the patents adequately disclosed and enabled the claimed combination.
5. Whether the ANDA filing created an artificial act of infringement under Section 271(e)(2).

The district court's decision is reported at 800 F. Supp. 2d 789 (E.D. Tex. 2011). [1]

The court treated the claimed invention as a combination with defined therapeutic and pharmaceutical characteristics. Par argued that the individual active ingredients were known and that combining them would have been an obvious development. Pozen countered that the prior art did not provide a sufficient reason to select the claimed combination and dosage relationship, nor did it establish a reasonable expectation of success.

The district court credited Pozen's position and entered judgment in Pozen's favor on infringement and validity issues.

What did the Federal Circuit decide?

The Federal Circuit affirmed the principal district court rulings in 2012. The appellate decision addressed claim construction, infringement, and obviousness.

Claim construction

The Federal Circuit reviewed the disputed claim terms under the ordinary principles applicable to patent interpretation. The court declined to adopt Par's narrower or otherwise noninfringing interpretations where those interpretations were inconsistent with the patent claims and specification.

The appellate ruling preserved the district court's reading of the claims covering Par's proposed sumatriptan/naproxen product.

Infringement

Par's ANDA product was found to meet the relevant limitations of the asserted composition and method claims. The infringement analysis focused on the product described in the ANDA, including the presence of both active ingredients and the claimed dosage and administration characteristics.

Because an ANDA filing is treated as an artificial act of infringement for purposes of resolving listed-patent disputes, Pozen did not need to wait for commercial launch to litigate the patent issues. The action therefore determined whether Par could obtain approval and launch before the relevant patent barriers expired.

Obviousness

The Federal Circuit upheld the nonobviousness determination. The court rejected Par's argument that the claimed combination followed predictably from the prior art.

The key points were:

• The prior art disclosed sumatriptan and naproxen as separate migraine therapies.
• The prior art did not establish that the specific combination would predictably provide the claimed therapeutic benefits.
• The claimed dosage relationship was material to the invention.
• The evidence did not show a sufficient motivation to combine the references with a reasonable expectation of success.
• Objective evidence supported the patentability of the claimed combination.

The ruling did not establish that combination-drug patents are categorically strong. It applied the obviousness analysis to the specific record, claim language, and expert evidence presented in the case.

How strong were Pozen's patents after the Federal Circuit ruling?

The patent estate was strong against the specific Par ANDA at issue because Pozen prevailed on both infringement and validity. The decision reduced the immediate risk that Par could launch the same combination product based on the challenged ANDA.

The estate's strongest features were:

Strength factor	Analysis
Defined active ingredients	The claims were directed to a specific sumatriptan/naproxen combination
Dosage limitations	The claimed dosage relationship limited the scope but supported differentiation from broad prior-art disclosures
Method claims	The '458 patent added method-of-treatment protection beyond the composition claims
ANDA record	Par's proposed product was described in sufficient detail to support an infringement finding
Federal Circuit affirmance	The validity and infringement rulings survived appellate review

The estate also had limitations. The claims did not broadly cover every migraine combination, every triptan/NSAID product, or every formulation containing either active ingredient. A competing product outside the claimed dosage, formulation, or method limitations could present a different infringement analysis.

The decision also did not eliminate later challenges based on different patents, later-developed prior art, or noninfringement positions involving a materially different product.

What were the patent expiration dates?

The original statutory terms of the principal patents were tied to their nonprovisional filing dates and were generally expected to expire in the late 2010s, subject to patent-term adjustment, patent-term extension, and pediatric exclusivity.

Patent	Earliest relevant filing period	Approximate statutory term
U.S. Patent No. 6,060,499	1997	June 2017, subject to term adjustments
U.S. Patent No. 6,586,458	1998	2018, subject to term adjustments

The precise commercial entry date could not be determined solely from the district court judgment. It depended on the final Orange Book listing, any later continuation patents, regulatory exclusivity, settlement terms, and whether Par prevailed in any separate patent or regulatory proceeding.

Pozen and its commercial partners also pursued later Treximet-related patents. Those later patents were distinct from the two patents adjudicated in Pozen v. Par and should not be treated as having been invalidated by the 2012 appellate decision.

What was the Paragraph IV challenge?

Par's ANDA included a Paragraph IV certification asserting that the listed Pozen patents were invalid, unenforceable, or not infringed. Pozen responded by filing the patent action within the Hatch-Waxman statutory period.

The Paragraph IV notice created the central dispute:

• Par sought FDA approval for a generic fixed-dose sumatriptan/naproxen product.
• Pozen alleged that the ANDA product would infringe the '499 and '458 patents.
• The filing triggered the statutory patent litigation framework.
• The court's judgment determined whether FDA approval could lead to an earlier generic launch.

The case was therefore a conventional ANDA patent dispute rather than a post-launch damages action. The primary commercial objective was control of the generic approval and launch timeline.

Did the case involve a settlement agreement?

The reported district court and Federal Circuit decisions reflect adjudication of the patent dispute and appellate review. The principal reported record does not establish a settlement as the basis for the judgment.

A settlement, if separately executed or later amended, would require review of the relevant agreement and regulatory filings. The reported appellate decision is analyzed as an affirmance of the district court's infringement and validity rulings, not as a settlement decision.

What was the FDA and Orange Book status of Treximet?

Treximet was approved by the FDA as a prescription combination tablet for acute migraine treatment. Its regulatory position was based on the combination of sumatriptan and naproxen sodium rather than on a new molecular entity.

The Orange Book functioned as the relevant source for listed patents and therapeutic-equivalence information. The litigation illustrates the difference between:

• FDA approval of the underlying drug product;
• Orange Book listing of patents;
• Paragraph IV challenges to listed patents;
• statutory regulatory exclusivity; and
• patent-based launch restrictions.

Treximet did not present a biosimilar pathway because it was a small-molecule drug. A competing product would proceed through the ANDA pathway, not through the biologics license application or biosimilar provisions of the Public Health Service Act.

What generic launch risks existed for Par?

Par faced substantial launch risk after the Federal Circuit affirmed the principal judgment.

Immediate launch risk

A commercial launch before the relevant patent barriers expired could expose Par to injunction proceedings and damages claims. The Federal Circuit affirmance removed the principal appellate basis for an early launch under the challenged ANDA.

Design-around risk

A noninfringing product would have needed to avoid the asserted claim limitations. Potential design-around variables included:

• active-ingredient amounts;
• dosage ratios;
• release characteristics;
• tablet architecture;
• administration instructions; and
• labeling language.

A design-around could still face other patents or induced-infringement allegations based on the proposed label.

Regulatory delay

Even if Par defeated the patents, FDA approval and any applicable regulatory exclusivity could affect launch timing. Conversely, expiration of the original patents would not necessarily eliminate later-issued patents with different claims.

Which companies were involved in the competitive landscape?

The principal entities were:

Entity	Role
Pozen Inc.	Inventor and patent owner
GlaxoSmithKline	Commercial partner and Treximet marketer at the relevant time
Par Pharmaceutical, Inc.	ANDA filer and proposed generic competitor
FDA	Regulator responsible for ANDA review and approval

The commercial value of the litigation was tied to Treximet sales and to Pozen's licensing economics. An adverse ruling could have accelerated generic competition and reduced branded revenue, pricing power, and royalty streams. The reported opinions do not provide a reliable quantified revenue figure for the product or the litigation's precise financial impact.

How does Pozen v. Par compare with ordinary formulation patent cases?

Pozen v. Par involved more than a conventional tablet-formulation dispute. The asserted claims covered a therapeutic combination and method of treatment, while also relying on dosage and pharmaceutical-composition limitations.

Issue	Pozen v. Par	Typical formulation case
Active ingredients	Two known active ingredients used together	Often one active ingredient in a new delivery system
Core patent theory	Combination therapy and dosage relationship	Release profile, excipient, coating, or dosage form
Main validity issue	Whether combining known agents was obvious	Whether formulation modification was routine
Infringement evidence	ANDA composition and proposed use	Manufacturing process, product testing, or ANDA description
Regulatory pathway	ANDA Paragraph IV	Usually ANDA Paragraph IV

The case is particularly relevant to combination-product strategies because it shows that known ingredients can support patent protection when the claims include a defensible dosage relationship, therapeutic rationale, and evidentiary record demonstrating nonobviousness.

Key Takeaways

• Pozen sued Par over an ANDA for a generic Treximet equivalent.
• The principal patents were U.S. Patent Nos. 6,060,499 and 6,586,458.
• The patents covered sumatriptan/naproxen compositions and migraine-treatment methods.
• The Eastern District of Texas found infringement and rejected Par's principal invalidity defenses.
• The Federal Circuit affirmed the principal judgment in 2012 at 696 F.3d 1151.
• The case strengthened Pozen's position against Par's specific ANDA.
• The ruling did not broadly validate every Treximet-related patent or prevent later challenges to continuation patents.
• Treximet was a small-molecule combination drug, so biosimilar rules were not relevant.
• Generic entry depended on patent expiration, later Orange Book listings, FDA approval, and any separate regulatory or contractual restrictions.

FAQs

What was the drug in Pozen v. Par?

The drug was Treximet, a fixed-dose combination of sumatriptan succinate and naproxen sodium used for acute migraine treatment.

What did Par's Paragraph IV certification challenge?

Par challenged Pozen's patents covering the sumatriptan/naproxen composition and methods for treating migraine with the combination.

Did Par win on obviousness?

No. The district court rejected Par's obviousness challenge, and the Federal Circuit affirmed the principal judgment.

Did Pozen v. Par involve biosimilar litigation?

No. Treximet is a small-molecule drug regulated through the ANDA pathway. The case was an ANDA patent dispute, not a biosimilar case.

Did the Federal Circuit invalidate the Treximet patent estate?

No. The Federal Circuit affirmed the principal rulings involving the asserted patents. The decision did not adjudicate every later-issued or continuation patent associated with Treximet.

References

1. Pozen Inc. v. Par Pharmaceutical, Inc., 800 F. Supp. 2d 789 (E.D. Tex. 2011).

2. Pozen Inc. v. Par Pharmaceutical, Inc., 696 F.3d 1151 (Fed. Cir. 2012).

3. U.S. Food and Drug Administration. (2008). Treximet prescribing information.

4. U.S. Patent and Trademark Office. (2000). U.S. Patent No. 6,060,499: Pharmaceutical compositions for the treatment of migraine.

5. U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,586,458: Methods for treating migraine.